2025 France Adult And Pediatric Vaccines Market Revenue Opportunities Report
Description
The 2025 France Adult And Pediatric Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult and Pediatric Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adult and Pediatric Vaccines Market in France are Sanofi, GlaxoSmithKline (GSK) Plc, Pfizer Inc., and Seqirus. Sanofi, headquartered in Paris, is a global leader through its Sanofi Pasteur division, offering a broad portfolio of vaccines including influenza and childhood immunization vaccines, playing a crucial role in the French vaccine market. GSK, having acquired Novartis’s vaccine division, is a major player in producing vaccines against diseases like influenza and meningitis. Pfizer is renowned for its innovative vaccines, notably its mRNA COVID-19 vaccine, and also provides vaccines for pneumococcal and meningitis infections. Seqirus is another prominent vaccine manufacturer active in France, focusing on influenza vaccines and contributing significantly to the market growth driven by safety and efficacy standards .
These companies invest extensively in research and development to meet stringent European regulatory standards overseen by agencies like EMA. Their vaccine portfolios cover both adult and pediatric vaccines, supporting France’s growing demand fueled by government vaccination programs and public health initiatives. Together, they dominate the vaccine market valued at approximately USD 2.8 billion in 2024, expected to reach over USD 4.7 billion by 2035 with a CAGR of 4.97%. Their strategies include compliance with rigorous safety regulations, innovation in vaccine technologies, and expanding access to immunization for diverse populations within France .
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult and Pediatric Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adult and Pediatric Vaccines Market in France are Sanofi, GlaxoSmithKline (GSK) Plc, Pfizer Inc., and Seqirus. Sanofi, headquartered in Paris, is a global leader through its Sanofi Pasteur division, offering a broad portfolio of vaccines including influenza and childhood immunization vaccines, playing a crucial role in the French vaccine market. GSK, having acquired Novartis’s vaccine division, is a major player in producing vaccines against diseases like influenza and meningitis. Pfizer is renowned for its innovative vaccines, notably its mRNA COVID-19 vaccine, and also provides vaccines for pneumococcal and meningitis infections. Seqirus is another prominent vaccine manufacturer active in France, focusing on influenza vaccines and contributing significantly to the market growth driven by safety and efficacy standards .
These companies invest extensively in research and development to meet stringent European regulatory standards overseen by agencies like EMA. Their vaccine portfolios cover both adult and pediatric vaccines, supporting France’s growing demand fueled by government vaccination programs and public health initiatives. Together, they dominate the vaccine market valued at approximately USD 2.8 billion in 2024, expected to reach over USD 4.7 billion by 2035 with a CAGR of 4.97%. Their strategies include compliance with rigorous safety regulations, innovation in vaccine technologies, and expanding access to immunization for diverse populations within France .
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
